Rheumatology and Immunology Department, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Front Immunol. 2021 Sep 1;12:700570. doi: 10.3389/fimmu.2021.700570. eCollection 2021.
Growing evidence suggests that the gut microbiota is involved in the initiation and progression of ankylosing spondylitis (AS). In this study, we aimed to explore the gut microbiome alterations during adalimumab therapy and verify microbiome biomarkers predicting treatment response. By evaluating the gut microbial features of 30 AS patients before and after adalimumab therapy for 6 months and 24 healthy controls, we confirmed that the microbiome was restored remarkably after 6 months of adalimumab therapy in AS patients. We then compared the baseline gut microbiome of 22 adalimumab responders with 8 non-responders, a higher abundance of was revealed in the latter, although no statistical difference was found after adjusting for the false discovery rate. These results suggested that adalimumab therapy restored the gut microbiome in AS patients and indicated the utility of gut microbiome to be potential biomarkers for therapeutic evaluation. These findings provided an insight into the development of predictive tools and the establishment of precise medical interventions for clinical practice.
越来越多的证据表明，肠道微生物群参与了强直性脊柱炎（AS）的发生和发展。在这项研究中，我们旨在探讨阿达木单抗治疗期间肠道微生物组的变化，并验证预测治疗反应的微生物组生物标志物。通过评估 30 例 AS 患者在阿达木单抗治疗 6 个月和 24 例健康对照者前后的肠道微生物特征，我们证实 AS 患者在阿达木单抗治疗 6 个月后，肠道微生物组得到了显著恢复。然后，我们比较了 22 例阿达木单抗应答者和 8 例无应答者的基线肠道微生物组，发现后者的 丰度更高，尽管在调整假发现率后没有发现统计学差异。这些结果表明，阿达木单抗治疗恢复了 AS 患者的肠道微生物组，并表明肠道微生物组有可能成为治疗评估的潜在生物标志物。这些发现为预测工具的开发和精确医疗干预措施的建立提供了临床实践的见解。
